LMEDLINE

Subject Coverage

All areas in the broad field of biomedicine.

File Type

Bibliographic

Features

Thesauri: Chemical Name (/CN), Controlled Term (/CT)
MeSH Tree Number (/MN)
The thesauri do not apply to terms in the OLDMEDLINE file segment.

CAS Registry Number® Identifiers	☑	Page Images	☐	STN® AnaVist™	☐
Keep & Share	☑	SLART	☑	STN Easy®	☐
Learning Database	☑	Structures	☐		

Record Content

- LMEDLINE is a static training database intended for learning how to use MEDLINE®.
- Over 99% of MEDLINE's citations are references to journal articles
- Approximately 50% of the citations contain abstracts
- Records added before 1975 do not have abstracts
- MEDLINE reference data is present in the file
- CAS Registry Numbers are present in the file
- About 75% of MEDLINE's citations represent publication in the English language

File Size

Approximately 18,686 records from OLDMEDLINE and MEDLINE (4/2017)

Coverage

Selected from 1948-present

Updates

None

Language

English

Database Producer

U.S. National Library of Medicine (NLM)
8600 Rockville Pike
Bethesda, MD 20894 USA
Phone: 301-594-5983
Phone: 888-346-3656

Sources

Over 5,300 journal titles published in over 70 countries are currently indexed in the full MEDLINE database

User Aids

- Medical Subject Headings - MeSH Browser: http://www.nlm.nih.gov/mesh/
- List of Serials Indexed for Online Users: http://www.nlm.nih.gov/tsd/serials/lsiou.html
- STNGUIDE
- Online Helps (HELP DIRECTORY lists help messages available)

Clusters

LEARNING
STN Database Clusters information (PDF)

Pricing

Enter HELP COST at an arrow prompt (=>).

Search and Display Field Codes

NLM represents that the databases provided hereunder were formulated with a reasonable standard of care. NLM makes no representations or warranties, expressed or implied, including but not limited to, any implied warranty of merchantability or fitness for a particular purpose, with respect to such databases and specifically disclaims all such warranties and representations. Some material in these databases is from copyrighted publications of the respective copyright claimants. Users of the databases are referred to the publications data appearing in the bibliographic citations, as well as to the copyright notices appearing in the original publication, all of which are hereby incorporated by reference.

The fields that allow left truncation are marked with an asterisk (*).

Search Field Name	Search Code	Search Examples	Display Codes
Basic Index * (contains single words from the title (TI), chemical name (CN), gene name (GEN), controlled term (excluding MeSH numbers) (CT), supplementary term (ST), named person (NA), other source (OS), and abstract (AB) fields, as well as CAS Registry Numbers and GenBank® Numbers)	None (or /BI)	S INTERFERON GAMMA S 50-02-2 S GENBANK D64071 S HEART (S) TEST# S ?FERON? S EC3.1.3.13 S GAMMA (S) INTERFERON	AB, CN, CT, GEN, NA, OS, RN, ST, TI
Abstract *	/AB	S ?ASSAY?/AB S RADIOACTIVE TRACER/AB S (LEUKEMIA (S) GLEEVEC)/AB	AB
Abstract Languages (other) **(3)**	/ABLA	S SPANISH/ABLA	ABLA
Accession Number	/AN	S 1965153674/AN S 1998010009/AN	AN
Accession Number of the Cited Reference in MEDLINE	/RAN.MED	S 1967176588/RAN.MED	RE
Author	/AU	S ADAMSON G?/AU	AU
Author Group	/AUTH	S BROOKS A?/AUTH	AUTH
Author Identifier	/AUID	S 0000-0001-8859-5034/AUID	AUID
Chemical Name **(1)**	/CN	S NIFEDIPINE/CN S EC 1.11.1.6/CN	CN, RN
Chemical Name Segment * **(1)**	/CNS	S ?FLUOR?/CNS	CN, RN
Cited Reference First Author Name	/RAU	S DEANDRADE A L/RAU	RE
Cited Reference First Author Name, Extended **(12)**	/RAU.EX	S WALKER J M?/RAU.EX	RE
Cited Reference Count **(6)**	/RE.CNT	S 15-20/RE.CNT	RE.CNT
Cited Reference Issue Number	/RIS	S 12/RIS	RE
Cited Reference Page Number	/RPG	S 32/RPG	RE
Cited Reference Publication Year	/RPY	S 2007/RPY	RE
Cited Reference Source Publication	/RSO	S JAMA/RSO	RE
Cited Reference Volume Number	/RVL	S 22/RVL	RE
Cited Reference Source Publication Name	/RWK	S MED ARTS SCI/RWK	RE
Cited References	/RE	S DELPHIA J M?/RE	RE
Cited References, Extended **(12)**	/RE.EX	S WALKER J M?/RE.EX	RE
Citing Reference Accession Numbers (limit 50)	/OS.G (or /OS.CITING.AN)	S 2014206241/OS.G	OS.G, OS.CITING.AN
Citing Reference Count **(6)**	/OSC.G (/CITING.CNT)	S 13/OSC.G	OSC.G, CITING.CNT
Clinical Trial Numbers	/NCT	S ISRCTN03464021/NCT S NCT00005487/NCT	NCT
Collaborators	/AUCL	S BEGAY JACK/AUCL	AUCL
Comment	/CM	S TOXICOL?/CM	CM
Controlled Term **(2)** (includes main terms)	/CT	S OVARIAN FOLLICLE/CT S (HYPERTENSION(L)BL)/CT S (C14.907.489. (L) TH)/CT S *BRAIN/CT	CT
Corporate Source **(3,4)** (includes Collective Name)	/CS	S (KYUSHU(W)CANCER(W)CENTER)/CS S ROSIGLITAZONE STUDY GROUP/CS	CS
Country of Publication (ISO code and text)	/CY	S L1 AND UNITED STATES/CY S JP/CY	CY

Search and Display Field Codes (cont'd)

Search Field Name	Search Code	Search Examples	Display Codes
Digital Object Identifier	/FTDOI (or /DOI)	S 10.11?/FTDOI	DOI, FTDOI
Document Number (contains MEDLINE DN and the PubMed ID number)	/DN	S 9875853/DN S 6000001/DN S 11300629/DN	DN
Document Type (code and text) **(5)**	/DT (or /TC)	S MULTICENTER STUDY/DT S BIO/TC	DT
Electronic Publication Date **(6)**	/EPD	S 21 DEC 2012	EPD, SO
Electronic Publication Year **(6)**	/EPY	S 2013/EPY	EPY, SO
Email Address **(3)**	/EML	S B.A.BRIDGES@SUSSEX.AC.UK/EML	CS, EML
Entry Date **(6)**	/ED	S ED>20020500	ED
Entry Month **(6)**	/EM	S 199106/EM	EM
Field Availability **(7)**	/FA	S L2 AND AB/FA	Not displayed
File Segment **(8)**	/FS	S L8 AND PRIORITY JOURNALS/FS S B/FS S DIABETES AND OLD/FS S IN-PROCESS/FS S CLINICAL TRIALS.GOV/FS	FS
Gene Name **(3,9)**	/GEN	S C-JUN/GEN	GEN
Grant Number **(3)**	/GN	S R01 HG005220/GN	GN
Grant Organization	/GO	S NHGRI/GO	GO
Group Authors	/AUGR	S DALLAS EVE/AUGR	AUGR
International Standard (Document) Number (contains CODEN, if available, and ISSN)	/ISN	S 8756-8160/ISN	ISN, SO
Journal Title (contains full and abbreviated journal titles)	/JT	S BIOCHEM PHARMACOL/JT S BIOCHEMICAL PHARMACOLOGY/JT	JT, SO
Journal Title Code **(3)**	/JTC	S 0101032/JTC	SO
Language (ISO code and text)	/LA	S GERMAN/LA S RU/LA	LA
MEDLINE Cited References Count **(6)**	/REM.CNT	S 5-10/REM.CNT	REM.CNT
Named Person **(10)**	/NA	S PRIMROSE J/NA	NA
Number of Report **(3)**	/NR	S NASA-00001303/NR S NASA/NR	NR, SO
Other Sources **(3,11)**	/OS	S CLML5936/OS S GENBANK L02896/OS	OS
Publication Date **(6)**	/PD	S 2005 OCT 4/PD	PD, SO
Publication Year **(6)**	/PY	S L1 AND 1990-1992/PY	PY, SO
Source (contains full and abbreviated journal titles, ISSN, CODEN, journal title code, number of report, space flight mission, investigator, and affiliation data, call number, publication year, volume, issue, and pagination)	/SO	S 0006-2952/SO S BIOCHEM PHARMACOL/SO S 7802429/SO S NASA00001303/SO S FLIGHT EXPERIMENT/SO	SO
Title *	/TI	S TOOTH MOVEMENT/TI	TI
Unique Ingredient Identifier	/UNII	S TE7660XO1C /UNII	UNII
Update Date **(6)**	/UP	S UP>20030200 AND L4	ED
Update Date Indexing Added **(6)**	/UPI	S UPI>20140528	ED, UPI
Date Last Citing Reference Entered STN **(6)**	/UPOS.G (or /UPOG, /CITING.UP)	S 20140107/UPOS.G S CITING.UP>20140107	UPOS.G, UPOG, CITING.UP

(1) CAS Registry Numbers and Enzyme Codes can also be searched in this field. A /CN Thesaurus is available online. Starting on November 19, 2000, a new relationship, +XUSE, has been defined for EXPAND and SEARCH in the /CN field. XUSE includes both USE and UF terms. When you EXPAND in the /CN field, a message is displayed if additional terms are available by using the +XUSE relationship. If there are additional USE or UF terms available for a search in the /CN field, they are automatically included in the search.

(2) MeSH Tree Numbers are also searched in this field. (L) proximity is available with Qualifiers. Postings for MeSH Headings do not include narrower terms, while MeSH Tree Numbers do include all narrower levels. /CT and /MN Thesauri are available online. Starting on November 19, 2000, a new relationship, +XUSE, has been defined for EXPAND and SEARCH in the /CT field. XUSE includes both USE and UF terms. When you EXPAND in the /CT field, a message is displayed if additional terms are available by using the +XUSE

relationship. If there are additional USE or UF terms available for a search in the /CT field, they are automatically included in the search.
(3) This field is not available for records in the OLDMEDLINE file segment.
(4) Search with implied (S) proximity is available in this field.
(5) Both STN standard document types and original NLM publication types (displayed in parenthesis) are searchable separately as bound phrases.
(6) Numeric search field that may be searched using numeric operators or ranges.
(7) The presence of AB, CN, CS, EML, NA, OS, RN, ST fields can be searched in the /FA field; as well as the sections of the structured abstract: Background, Conclusions, Methods, Objective, and Results.
(8) Enter HELP FS at an arrow prompt for definitions of the FS codes.
(9) Data indexed in this field only until 1996.
(10) Subject of biographical or related article.
(11) Enter HELP OS for information on the content of this field.
(12) The EXPAND command is not available for use in this field.
(13) When author's name entered with multiple initials, automatically also searches the author's name with a single initial.

Limiting Search Codes

Only an answer set created in MEDLINE may be limited. L-number answer sets created by as search in the /ED or /UP field may also be limited.

Search Field Name	Search Code	Search Examples
Animal Subject **(1)**	/ANIMAL	S L4/ANIMAL
English-Language Records	/ENG	S L1/MAJ,ENG **(2,3)**
Female Subject **(1)**	/FEMALE	S L3/FEMALE
Human Subject **(1)**	/HUMAN	S L1/HUMAN
Major Descriptor **(1)**	/MAJ	S L1/MAJ
Male Subject **(1)**	/MALE	S L2/MALE

(1) Not available in OLDMEDLINE file segment.
(2) Field codes may be abbreviated to the first three letters.
(3) Answer sets may be limited to more than one area.

Chemical Name (/CN) Thesaurus

All Relationship Codes can be used with both the SEARCH and EXPAND command in the Chemical Name (/CN) thesaurus.

The /CN thesaurus does not apply to the OLDMEDLINE file segment.

Code	Content	Examples
ALL	All associated terms (SELF, CN, RN, EC, UF, USE, RR, HM, PA, INDX, NOTE, PNTE, RE)	E CHAETOGLOBOSINS+ALL/CN E 86414-29-1+ALL/CN
AUTO **(1)**	Automatic Relationship Code (SELF, USE)	E BROMOACETIC ACID+AUTO/CN
HM	Heading Mapped to (SELF, CN, RN, EC, RR, HM)	E CADMIUM ACETATE+HM/CN
NOTE	Notes associated with the term (SELF, CN, RN, EC, RR, INDX, PA, NOTE, PNTE, RE)	E SERICYSTATIN+NOTE/CN E EC 2.4.1.119+NOTE/CN
PFT	Preferred and Forbidden Terms (SELF, CN, RN, EC, RR, UF, USE)	E COMBRETASTATIN+PFT/CN
RN	CAS Registry Number associated with the name or name associated with a CAS Registry Number (SELF, CN, RN, EC)	S ARGINYLPROLINE+RN/CN E 2418-69-1+RN/CN
RR	Associated CAS Registry Numbers and UNII Codes (SELF, CN, RN, EC, RR)	E FLUVALINATE+RR/CN E BKJ8M8G5HI+RR/CN
XUSE	USE and UF terms from the current MeSH	E 6-CHRYSENYLAMINE+XUSE/CN S 6-CHRYSENAMINE+XUSE/CN

(1) AUTOMATIC relationship is SET OFF. In case of SET REL ON, the result of EXPAND without any relationship code is the same as described for AUTO.

Field Descriptors for the /CN Thesaurus

Code	Description
-->	Self
CN	Chemical Name and Enzyme Name
EC	Enzyme Commission Numbers
HM	Heading Mapped To
INDX	Indexer Note
NOTE	Scope Note
PA	Pharmacological Action
PNTE	Previous Indexing Note
RE	Reference
RN	CAS Registry Number
RR	Related Registry Numbers and UNII Codes
UF	Used For
USE	Use

Controlled Term (/CT) Thesaurus

All Relationship Codes can be used with both the SEARCH and EXPAND command in the Controlled Term (/CT) thesaurus.

The /CT thesaurus contains the current Controlled Terms. MeSH Tree Numbers are searchable terms in the /CT thesaurus.

The /CT and /MN Thesauri have the same EXPAND abilities except when expanding MeSH Tree Numbers. The /CT Thesaurus will expand the same Tree Number hierarchy, while the /MN Thesaurus will expand the MeSH terms corresponding to the various MeSH Tree Numbers.

The /CT thesaurus does not apply to the OLDMEDLINE file segment.

Code	Content	Examples
ALL	All associated terms (BT, SELF, MN, DC, NOTE, INDX, ENTC, AQ, PNTE, HNTE, MHTH, BXTH, PA, UF, USE, QUSE, NT, QLF, QA, QCAT, QNOTE, QINDX, QHNTE, QONTE, QUF, RT)	E PEPTIC ULCER+ALL/CT E C6.405.608+ALL/CT
AUTO **(1)**	Automatic Relationship Code (Preferred Terms and Qualifiers) (SELF, USE, QUSE)	E NASAL SINUSES+AUTO/CT E ADV EFF+AUTO/CT
BT	Broader Terms (BT, SELF, MN)	E PREGNANCY TESTS+BT/CT
HIE	Hierarchy (Broader and Narrower Terms) (BT, SELF, MN, NT)	E RECEPTORS, DRUG+HIE/CT
KT	Keyword Terms (SELF, KT)	S SHOCK+KT/CT
MN	Tree Number and descriptor class (SELF, MN, DC)	E PROSTHESIS FAILURE+MN/CT S NUTRITIONAL STATUS+MN/CT
NOTE	Notes associated with the term (SELF, MN, NOTE, INDX, ENTC, AQ, PNTE, HNTE, ONTE, MHTH, BXTH, PA)	E PEPTIC ULCER+NOTE/CT
NT	Narrower Terms (SELF, MN, NT)	S NEURONS+NT/CT
PFT	Preferred and Forbidden Terms (SELF, MN, ENTC, AQ, UF, USE)	E FIBRIN TISSUE ADHESIVE+PFT/CT
QLF	Qualifier and associated terms (SELF, AQ, QUSE, QLF, QA, QCAT, QNOTE, QINDX, QHNTE, QONOTE, QUF)	S ADVERSE EFFECTS+QLF/CT
QPFT	Qualifier Preferred (SELF, QUSE, QLF, QUF)	E PSYCHOLOGY+QPFT/CT
RT	Related Terms (SELF, MN, RT)	E NEURONS+RT/CT
STD	Standard (Broader, Narrower, and Related Terms) (BT, SELF, MN, NT, RT)	S SPINAL CORD+STD/CT E PNEUMONIA+STD/CT
UF	Used For (Forbidden Terms) (SELF, MN, UF)	E F1.145.775.+UF/CT E SEX BEHAVIOR+UF/CT
USE	Use (Preferred Terms) (SELF, MN, USE)	E GRAAFIAN FOLLICLE+USE/CT
XUSE	USE and UF terms from the current MeSH	E RADICULITIS+XUSE/CT

(1) AUTOMATIC relationship is SET OFF. In case of SET REL ON, the result of EXPAND without any relationship code is the same as described for AUTO.

Field Descriptors for the /CT Thesaurus

Code	Description
-->	Self
AQ	Allowable Qualifier
BT	Broader Term
BXTH	Backwards Cross Reference Thesaurus
DC	Descriptor Class
ENTC	Entry Combination
HNTE	History Note
INDX	Indexer Note
KT	Keyword Terms
MH	MeSH Heading
MHTH	MH Thesaurus
MN	MeSH Tree Number
NOTE	Scope Note, Consider Also Terms
NT	Narrower Term
ONTE	Online Note
PA	Pharmacological Action
PNTE	Previous Indexing Note
QA	Qualifier Abbreviation
QCAT	Allowable Categories
QHNTE	Qualifier History Note
QINDX	Qualifier Indexer Note
QLF	MeSH Qualifier (subheading)
QNOTE	Qualifier Scope Note
QONTE	Qualifier Online Note
QUF	Qualifier Use For
QUSE	Qualifier Use
RT	Related Term
UF	Used For
USE	Use

MeSH Tree Number (/MN) Thesaurus

In the MeSH Tree Number (/MN) Thesaurus, all Relationship Codes can be used only with the EXPAND command.

The /MN Thesaurus does not have any postings. When searching, it is necessary to edit the field code to /CT.

The /CT and /MN Thesauri have the same EXPAND abilities except when expanding MeSH Tree Numbers. The /CT Thesaurus will expand the same Tree Number hierarchy, while the /MN Thesaurus will expand the MeSH terms corresponding to the various MeSH Tree Numbers.

The /MN thesaurus does not apply to the OLDMEDLINE file segment.

Code	Content	Examples
ALL	All associated terms (BT, SELF, MN, MH, EC, DC, NOTE, INDX, ENTC, AQ, PNTE, HNTE, ONTE, MHTH, BXTH, PA, UF, USE, QUSE, NT, QLF, QA, QCAT, QNOTE, QINDX, QHNTE, QONTE, QUF, RT)	E GRANULOMA+ALL/MN E C23.550.382+ALL/MN
AUTO **(1)**	Automatic Relationship Code (Preferred Terms and Qualifiers) (SELF, USE, QUSE)	E PANCREATIC CHOLERA+AUTO/MN
BT	Broader Terms (BT, SELF, MN, MH)	E ILLUSIONS+BT/MN
HIE	Hierarchy (Broader and Narrower Terms) (BT, SELF, MN, MH, NT)	E CHLAMYDIA+HIE/MN E B3.440.190.190.190.+HIE/MN
KT	Keyword Terms (SELF, KT)	E DIET+KT/MN
MN	Tree Number and descriptor class (SELF, MN, MH, DC)	E ABSCESS+MN/MN
NOTE	Notes associated with the term (SELF, MN, MH, NOTE, INDX, ENTC, AQ, PNTE, HNTE, ONTE, MHTH, BXTH, PA)	E SPINAL NERVES+NOTE/MN E A8.800.350.380+NOTE/MN
NT	Narrower Terms (SELF, MN, MH, NT)	E TOOTH+NT/MN
PFT	Preferred and Forbidden Terms (SELF, MN, MH, ENTC, AQ, UF, USE)	E HUMAN ADENOVIRUSES+PFT/MN E B4.909.777.731.589.520+PFT/MN
QLF	Qualifier and associated terms (SELF, AQ, QUSE, QLF, QA, QCAT, QNOTE, QINDX, QHNTE, QONTE, QUF)	E AE+QLF/MN
QPFT	Qualifier Preferred (SELF, QUSE, QLF, QUF)	E METABOLISM+QPFT/MN
RT	Related Terms (SELF, MN, MH, RT)	E TOMOGRAPHY, EMISSION-COMPUTED+RT/MN
STD	Standard (Broader, Narrower, and Related Terms) (BT, SELF, MN, MH, NT, RT)	E ALCOHOLISM+STD/MN E C21.739.100.250.+STD/MN
UF	Used For (Forbidden Terms) (SELF, MN, MH, UF)	E IODIDE PEROXIDASE+UF/MN
USE	Use (Preferred Terms) (SELF, MN, MH, USE)	E OPHTHALMIA+USE/MN
XUSE	USE and UF terms from the current MeSH	E ARSENIC POISONING+XUSE/MN

(1) AUTOMATIC relationship is SET OFF. In case of SET REL ON, the result of EXPAND without any relationship code is the same as described for AUTO.

Field Descriptors for the /MN Thesaurus

Code	Description
-->	Self
AQ	Allowable Qualifier
BT	Broader Term
BXTH	Backwards Cross Reference Thesaurus
DC	Descriptor Class
ENTC	Entry Combination
HNTE	History Note
INDX	Indexer Note
KT	Keyword Terms
MH	MeSH Heading
MHTH	MH Thesaurus
MN	MeSH Tree Number
NOTE	Scope Note, Consider Also Terms
NT	Narrower Term
ONTE	Online Note
PA	Pharmacological Action
PNTE	Previous Indexing Note
QA	Qualifier Abbreviation
QCAT	Allowable Categories
QHNTE	Qualifier History Note
QINDX	Qualifier Indexer Note
QLF	MeSH Qualifier (subheading)
QNOTE	Qualifier Scope Note
QONTE	Qualifier Online Note
QUF	Qualifier Use For
QUSE	Qualifier Use
RT	Related Term
UF	Used For
USE	Use

DISPLAY and PRINT Formats

Any combination of formats can be used to display or print answers. Multiple codes must be separated by spaces or commas, e.g., D L1 1-5 TI AU. The fields are displayed in the order requested.

Hit-term highlighting is available in all fields except CM, ED, and PY. Highlighting must be ON to use the HIT, HITIND, KWIC, and OCC formats.

Format	Content	Examples
AB	Abstract	D 1-5 AN, AB
ABLA	Abstract Language (other)	D ABLA
AN **(1)**	Accession Number	D 1-5 AN
AU	Author	D AU TI 2
AUCL	Collaborators	D AUCL
AUGR	Group Authors	D AUGR
AUID	Author Identifier	D AUID
AUPB **(2,4)**	Authors in Publication Order	D AUPB
AUTH	Author Group	D AUTH
CM **(1)**	Comment	D AN CM TI 1-5
CN **(1)**	Chemical Name (enzyme code and name)	D CN, RN 8-10
CS **(1)**	Corporate Source	D CS, AU 10-20
CT **(1)**	Controlled Term (MeSH terms, qualifiers)	D AN CT 1-2
CY **(1)**	Country of Publication	D CY TI
DN **(1)**	Document Number and PubMed ID	D DN
DOI (FTDOI)	Digital Object Identifier	D DOI, D FTDOI
DT **(1)**	Document Type	D DT TI
ED **(1)**	Entry Dates	D ED
EM **(1)**	Entry Month	D TI SO EM
EML **(1,2)**	E-mail Address	D EML
EPD **(1,2)**	Electronic Publication Date	D EPD
EPY **(1,2)**	Electronic Publication Year	D EPY
FS **(1)**	File Segment	D FS TI 1-2
GEN **(1)**	Gene Name	D GEN TI 1-2
GN	Grant Number	D GN
GO	Grant Organization	D GO
ISN **(1,2)**	International Standard (Document) Number	D 2 6 ISN
ISSUE **(2)**	Issue	D ISSUE
JT **(1,2)**	Journal Title (includes JTA and JTF)	D 1-3 JT
JTA **(1,2)**	Journal Title, Abbreviated	D JTA
JTF **(1,2)**	Journal Title, Full	D JTF
LA **(1)**	Language	D LA TI
NA **(1)**	Named Person (subject of biography or related article)	D AN TI NA
NCT	Clinical Trial Numbers	D NCT
NR **(1,2)**	Number of Report	D NR
OS **(1)**	Other Source	D TI SO OS
OS.G (OS.CITING.AN)	Citing Reference Accession Numbers (up to 50 accession numbers)	D OS.G
OS.GMAX	Citing Reference Accession Numbers (up to 1020 accession numbers)	D OS.GMAX
OSC.G (CITING.CNT)	Citing Reference Count	D OSC.G
PD **(1,2)**	Publication Date	D PY SO
PGNO **(2)**	Page Number	D PGNO
PY **(1,2)**	Publication Year	D PY
RE	MEDLINE Cited References	D RE
RE.CNT (REC)	Cited References Count	D RE.CNT
REM.CNT	MEDLINE Cited References Count	D REM.CNT
RN **(1)**	CAS Registry Number (Registry Number and chemical name)	D CT RN
SO	Source	D SO TI FS
ST **(1)**	Supplementary Term	D ST
TC **(1,2)**	Treatment Code	D TC
TI **(1)**	Title	D TI 1-10
UNII	Unique Ingredient Identifier	D UNII
UP	Update Date	D UP
UPI	Update Date Indexing Added	D UPI, D ED
UPOS.G (CITING.UP)	Date Last Citing Reference Entered STN	D UPOS.G
VL **(2)**	Volume	D VL

Display and Print Formats (cont'd)

Format	Content	Examples
ABS	AB, ABLA	D ABS 1-3
ALL	AN, DN, TI, AU.CS, SO, DOI, CM, CY, DT, LA, FS, NCT, OS, EM, ED, AB, ABLA, ST, CT, RN, CN, UNII, GO, GN, NA, GEN, OSC.G, UPOS.G, OS.G, RE.CNT, REM.CNT, RE	D 1-3 ALL
AU.CS	AU, AUID, CS (AU,AUID, CS repeat as needed), AUGR, AUID, CS (AUGR, AUID, CS repeat as needed), AUCL	D AU.CS
AUTH	AU, AUCL, AUGR	D AUTH
BIB	AN, DN, TI, AU.CS, SO, DOI, CY, DT, LA, FS, NCT, OS, EM, ED, UP, GO, GN, OSC.G, UPOS.G, OS.G, RE.CNT, REM.CNT (BIB is the default)	D 8 BIB
CBIB	Compressed bibliographic information	D 2 CBIB
DALL	ALL, delimited for post-processing	D DALL
IABS	ABS, with a text label	D IAB
IALL	ALL, indented with text labels	D IALL
IBIB	BIB, indented with text labels	D IBIB
IND **(1)**	CT, ST, RN, CN, UNII, NA, GEN	D BIB, IND
OSG	OSC.G, UPOS.G, OS.G (up to 50 accession numbers)	D OSG
OSG.MAX	OSC.G, UPOS.G, OS.G (up to 1020 accession numbers)	D OSG.MAX
RAN.MEDLINE (n)	Cited Reference(s) display feature (n=cited reference number(s)	D RAN.MEDLINE (n)
RETAB (RETABLE)	MEDLINE Cited References Table	D RETAB
SCAN **(3)**	TI, ST, CT, RN, CN, NA, GEN (random display without answer numbers)	D SCAN
TRIAL (FREE, SAM) **(1)**	TI, ST, CT, RN, CN, NA, GEN	D TRI
HIT	Fields containing hit terms	D HIT 5-10
HITIND **(1)**	IND	D HITIND
KWIC	Hit term with 20 words on either side (KeyWord-In-Context)	D KWIC 5-10
OCC **(1)**	Fields that contain hit terms and number of times they occur	D OCC L3 1-2

(1) No online display fee for this format.
(2) Custom display only.
(3) SCAN must be specified on the command line, i.e., D SCAN or DISPLAY SCAN.
(4) If 100 or more authors are provided, only the first 99 are presented followed by et al.

Displaying MEDLINE documents for cited references

Enter the following in the DISPLAY command: L-number for the answer set; answer number (only one may be specified); RAN.MEDLINE(x-y) where (x-y) is the cited reference number, numbers, or range of numbers; and the display format for the document to display, e.g., BIB ABS. For example, to display MEDLINE records for the cited references 1 and 2 from answer 2 in the answer set L5, enter the following:

=> D L5 2 RAN.MEDLINE(1-2) BIB ABS

SELECT, ANALYZE, and SORT Fields

The SELECT command is used to create E-numbers containing terms taken from the specified field in an answer set.

The ANALYZE command is used to create an L-number containing terms taken from the specified field in an answer set.

The SORT command is used to rearrange the search results in either alphabetic or numeric order of the specified field(s).

Field Name	Field Code	ANALYZE/ SELECT (1)	SORT
Abstract	AB	Y	N
Abstract Language (other)	ABLA	Y	N
Accession Number	AN	Y	N
Accession Number of the Cited Reference in MEDLINE	RAN.MED	Y	N
Author	AU	Y	Y
Author Group	AUTH	Y	N

SELECT, ANALYZE, and SORT Fields (cont'd)

Field Name	Field Code	ANALYZE/ SELECT (1)	SORT
Author Identifier	AUID	Y	Y
Authors in Publication Order	AUPB	Y **(12)**	N
CAS Registry Number	RN	Y **(2,3,4)**	N
Chemical Name	CN	Y **(4)**	N
	NAME	Y **(2,4)**	N
Chemical Name and CAS Registry Number	CHEM	Y **(2,4)**	N
Citation	CIT	Y **(4,5)**	N
Cited Reference First Author	RAU	Y	N
Cited Reference Publication Year	RPY	Y	N
Cited Reference Publication Name	RWK	Y	N
Cited References	RE	Y	N
Cited References Count	RE.CNT	Y	Y
Citing Reference Accession Numbers	OS.G (OS.CITING.AN)	Y	Y
Citing Reference Count	OSC.G (CITING.CNT)	Y	Y
Clinical Trial Numbers	NCT	Y	Y
Collaborators	AUCL	Y	N
Comment	CM	Y **(10)**	N
Corporate Source	CS	Y	Y
Controlled Term	CT	Y	N
Country of Publication	CY	Y	Y
Document Number	DN	Y **(6)**	Y
Document Type	DT	Y	Y
Email Address	EML	Y	Y
Electronic Publication Date	EPD	Y	Y
Electronic Publication Year	EPY	Y	Y
Entry Month	EM	Y	Y
File Segment	FS	Y	Y
GenBank Number	GENBANK (GBN)	Y **(2,11)**	N
Gene Name	GEN	Y	N
Grant Number	GN	Y	Y
Grant Organization	GO	Y	Y
Group Author	AUGR	Y	Y
Hit Cited Reference	HITRE	N	Y
International Standard (Document) Number (ISSN)	ISN	Y **(7)**	N
International Standard Serial Number	ISSN	N	Y
Journal Title	JT	Y	Y
Journal Title, Abbreviated	JTA	Y **(8)**	Y
Journal Title, Full	JTF	Y **(8)**	Y
Journal Title Code	JTC	Y	Y
Language	LA	Y	Y
MEDLINE Cited References Count	REM.CNT	Y	Y
Named Person	NA	Y	Y
Number of Report	NR	Y	Y
Occurrence Count of Hit Terms	OCC	N	Y
Other Source	OS	Y	Y
Publication Date	PD	Y	Y
Publication Year	PY	Y **(4)**	Y
Source	SO	Y **(9)**	N
Supplementary Term	ST	Y **(2)**	N
Title	TI	Y (default)	Y
Treatment Code	TC	Y	Y
Unique Ingredient Identifier	UNII	Y	N
Date Last Citing Reference Entered STN	UPOS.G (UPOG, CITING.UP)	Y	Y

(1) HIT may be used to restrict terms extracted to terms that match the search expression used to create the answer set, e.g., SEL HIT TI.
(2) Appends /BI to the terms created by SELECT.
(3) Only extracts CAS Registry Numbers.
(4) SELECT HIT and ANALYZE HIT are not valid with this field.
(5) Extracts first author, publication year, volume, and first page with a truncation symbol appended and with /RE appended to the terms created by SELECT. This field can be used for cross-file searching in SCISEARCH and CAplus[SM].
(6) Selects or analyzes MEDLINE's Document Number and the PubMed ID.

(7) Selects or analyzes the ISSN and CODEN.
(8) Appends /JT to the terms created by SELECT.
(9) Selects or analyzes the ISSN, CODEN, and journal code with /SO appended to the terms created by SELECT.
(10) Selects or analyzes the PMID values with /DN appended.
(11) SELECT GENBANK selects GenBank numbers from the OS field.
(12) Appends /AU to the terms created by SELECT.

Sample Records

DISPLAY IALL

```
ACCESSION NUMBER:    2010222995     LMEDLINE  Full-text
DOCUMENT NUMBER:     PubMed ID: 20202800
TITLE:               Drug attitude as predictor for effectiveness in
                     first-episode schizophrenia: Results of an open randomized
                     trial (EUFEST).
AUTHOR:              Gaebel Wolfgang
CORPORATE SOURCE:    Department of Psychiatry and Psychotherapy,
                     Heinrich-Heine-University Dusseldorf, Rhineland State
                     Clinics Dusseldorf, Germany.
                     wolfgang.gaebel@uni-duesseldorf.de
AUTHOR:              Riesbeck Mathias; von Wilmsdorff Martina; Burns Tom; Derks
                     Eske M; Kahn Rene S; Rossler Wulf; Fleischhacker W Wolfgang
GROUP AUTHORS:       Group Authors:  EUFEST Study Group
COLLABORATORS:       Collaborators: Kahn R S; Fleischhacker W W; Boter H; Keet
                     I P M; Brugman C; Davidson M; Dollfus S; Gaebel W;
                     Galderisi J; Gheorghe M; Gonen I; Grobbee D E; Hranov L G;
                     Hummer M; Libiger J; Lindefors N; Lopez-Ibor J J; Nijssen
                     K; Peuskens J; Prelipceanu D; Riecher-Rossler A; Rybakowski
                     J K; Sedvall G; Wilmsdorff M v
SOURCE:              European neuropsychopharmacology : the journal of the
                     European College of Neuropsychopharmacology, (2010 May)
                     Vol. 20, No. 5, pp. 310-6.  Electronic Publication Date: 3
                     Mar 2010
                     Journal code: 9111390. E-ISSN: 1873-7862. L-ISSN:
                     0924-977X.
DIGITAL OBJECT ID:   http://dx.doi.org/10.1016/j.euroneuro.2010.02.001
PUB. COUNTRY:        Netherlands
DOCUMENT TYPE:       Journal; Article; (JOURNAL ARTICLE)
                     (RANDOMIZED CONTROLLED TRIAL)
                     (RESEARCH SUPPORT, NON-U.S. GOV'T)
                     (CLINICAL TRIAL)
LANGUAGE:            English
FILE SEGMENT:        MEDLINE; Priority Journals
FILE SEGMENT:        Print; Electronic
ENTRY MONTH:         201006
ENTRY DATE:          Entered STN: 1 Apr 2010
                     Last Updated on STN: 15 Jun 2010
                     Entered Medline: 14 Jun 2010
ABSTRACT:
Effectiveness has become more and more important as a comprehensive outcome
measure for (long-term) treatment in schizophrenia.  Early predictors to
identify patients at a high risk for not succeeding the initiated treatment
would be very useful.  Discontinuation of the initiated treatment was used as
• • •
These findings have to be validated in other (first-episode) samples.
2010 Elsevier B.V. and ECNP. All rights reserved.
CONTROLLED TERM:     Check Tags: Female; Male
                      Adult
                     *Antipsychotic Agents: TU, therapeutic use
                      Benzodiazepines: TU, therapeutic use
                      Dibenzothiazepines: TU, therapeutic use
                      Haloperidol: TU, therapeutic use
                      Humans
                     *Medication Adherence: PX, psychology
                      Piperazines: TU, therapeutic use
                      Psychiatric Status Rating Scales
```

```
                     Questionnaires
                     ROC Curve
                    *Schizophrenia: DT, drug therapy
                    *Schizophrenic Psychology
                     Sulpiride: AA, analogs & derivatives
                     Sulpiride: TU, therapeutic use
                     Thiazoles: TU, therapeutic use
                     Treatment Outcome
CAS REGISTRY NO.:   12794-10-4 (Benzodiazepines); 132539-06-1 (olanzapine);
                    146939-27-7 (ziprasidone); 15676-16-1 (Sulpiride);
                    53583-79-2 (sultopride); 52-86-8 (Haloperidol)
CHEMICAL NAME:      Antipsychotic Agents; Dibenzothiazepines; Piperazines;
                    Thiazoles; quetiapine
UNIQ INGREDIENT ID: 6UKA5VEJ6X; 7MNE9M8287; AA0G3TW31W; BGL0JSY5SI; J6292F8L3D
OS.CITING REF COUNT: 3    There are 3 MEDLINE records that cite this record
DATE LAST CITED:    Date last citing reference entered STN: 23 Feb 2013
OS.CITING.REFS:     MEDLINE 2013403009; 2012930008; 2011244493
```

DISPLAY IALL (OLDMEDLINE File Segment)

```
ACCESSION NUMBER:   1960000021     LMEDLINE
DOCUMENT NUMBER:    PubMed ID: 13680875
TITLE:              The effect of atropine, propantheline and poldine on the
                    vagally stimulated gastric motility and the
                    histamine-stimulated acid gastric secretion in the rat.
AUTHOR:             AARSEN P N; van NOORDWIJK J
SOURCE:             British journal of pharmacology and chemotherapy, (1961
                    Aug) Vol. 17, pp. 41-50.
                    Journal code: 0154627. ISSN: 0366-0826. L-ISSN: 0366-0826.
DOCUMENT TYPE:      Journal; Article; (JOURNAL ARTICLE)
LANGUAGE:           English
FILE SEGMENT:       OLDMEDLINE; NONMEDLINE
OTHER SOURCE:       NLMPMC1482058
ENTRY MONTH:        199811
ENTRY DATE:         Entered STN: 16 Jul 1999
                    Last Updated on STN: 16 Jul 1999
                    Entered Medline: 1 Nov 1998
ABSTRACT:
Histamine-induced acid gastric secretion in the anaesthetized rat was not
diminished by poldine in a dose which reduced vagally stimulated gastric
contractions by approximately 75%.  A dose of atropine, twice as large as the
dose which reduced gastric contractions by 75%, had no apparent effect on the
histamine-stimulated acid gastric secretion up to 2 hr after the injection.
Only when more than 40 times as much atropine was injected did a slight
inhibition of the acid secretion occur in 80 to 120 min.  Propantheline, in a
dose which inhibited gastric contractions by approximately 75%, slightly
diminished acid secretion in 40 to 80 min.  This effect was not increased by a
further dose of propantheline.  It was concluded that, in so far as any
inhibition of acid gastric secretion had occurred, this could not be
interpreted as an anti-muscarine or a direct toxic effect, but rather as an
indirect effect possibly due to interference with the blood flow through the
stomach wall.
SUPPLEMENTARY TERM: atropine - pharmacology; gastric juice; histamine -
                    pharmacology; methantheline - related compounds;
                    parasympatholytics - pharmacology; stomach
CONTROLLED TERM:    *Atropine: PD, pharmacology
                    *Gastric Juice
                    *Histamine: PD, pharmacology
                    *Parasympatholytics: PD, pharmacology
                     Quaternary Ammonium Compounds
                    *Stomach
CAS REGISTRY NO.:   5818-17-7 (methantheline); 51-45-6 (Histamine); 51-55-8
                    (Atropine)
CHEMICAL NAME:      Parasympatholytics; Quaternary Ammonium Compounds
UNIQ INGREDIENT ID: 36EI79TX7I
OS.CITING REF COUNT: 1    There are 1 MEDLINE records that cite this record
```

```
MEDLINE REFERENCE COUNT:   8     There are 8 cited references available in
                                 MEDLINE for this document.
REFERENCE(S):   CITED REFERENCES AVAILABLE IN MEDLINE
(1) ACRED, P; Br J Pharmacol Chemother. 1957 Dec, V12(4), P447-52. MEDLINE
(2) CODE, C F; Pharmacol Rev. 1951 Mar, V3(1), P59-106. MEDLINE
(3) GHOSH, M N; Br J Pharmacol Chemother. 1958 Mar, V13(1), P54-61. MEDLINE
(4) HOLLANDER, F; Am J Physiol. 1956 Sep, V186(3), P373-6. MEDLINE
(5) NORDGREN, B; Acta Physiol Scand. 1957 Oct 22, V40(4), P297-304. MEDLINE
(6) Polland, W S; J Clin Invest. 1930 Oct, V9(2), P319-32. MEDLINE
(7) THOMPSON, J E; J Physiol. 1953 Sep, V121(3), P433-44. MEDLINE
(8) VAN NOORDWIJK, J; Br J Pharmacol Chemother. 1954 Sep, V9(3), P253-9.
     MEDLINE
```

DISPLAY BIB

```
AN   2014023012     LMEDLINE
DN   PubMed ID: 24076990
TI   Cas9 as a versatile tool for engineering biology.
AU   Mali Prashant
CS   Department of Genetics, Harvard Medical School, Boston, Massachusetts,
     USA.
AU   Esvelt Kevin M; Church George M
AUID ORCID: http://orcid.org/0000-0001-8797-3945
SO   Nature methods, (2013 Oct) Vol. 10, No. 10, pp. 957-63.
     Journal code: 101215604. E-ISSN: 1548-7105. L-ISSN: 1548-7091.
     Report No.: NLM-NIHMS585731; NLM-PMC4051438.
DOI  http://dx.doi.org/10.1038/nmeth.2649
CY   United States
DT   Journal; Article; (JOURNAL ARTICLE)
     (RESEARCH SUPPORT, N.I.H., EXTRAMURAL)
     (RESEARCH SUPPORT, NON-U.S. GOV'T)
     (RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.)
     General Review; (REVIEW)
LA   English
FS   MEDLINE; Priority Journals
FS   Print
EM   201312
ED   Entered STN: 1 Oct 2013
     Last Updated on STN: 20 Dec 2013
     Entered Medline: 11 Dec 2013
GO   United States NHGRI NIH HHS
GN   P50 HG005550
OSC.G 30      There are 30 MEDLINE records that cite this record
REM.CNT 75    There are 75 cited references available in MEDLINE for this
              document.
```

DISPLAY TRIAL

```
TI   Combination therapy using aspirin-enhanced photodynamic selective drug
     delivery.
CT    Animals
     *Aspirin: PD, pharmacology
     *Blood Vessels: DE, drug effects
      Chick Embryo
      Combined Modality Therapy
      Cyclooxygenase Inhibitors: PD, pharmacology
     *Drug Delivery Systems
      Fluorescein Angiography
      Heparin: PD, pharmacology
      Macular Degeneration: DT, drug therapy
      Macular Degeneration: TH, therapy
      Neoplasms: DT, drug therapy
      Neoplasms: TH, therapy
     *Photochemotherapy: MT, methods
      Photosensitizing Agents: PD, pharmacology
      Porphyrins: PD, pharmacology
RN   129497-78-5 (verteporfin); 50-78-2 (Aspirin); 9005-49-6 (Heparin)
CN   Cyclooxygenase Inhibitors; Photosensitizing Agents; Porphyrins
```

EXPAND in /CN Thesaurus

```
=> E NIFENALOL+ALL/CN
E1            0   -->  nifenalol/CN
E2            0   RN   5054-57-9/CN
E3            0     RR   5302-35-2/CN
                         ((R)-isomer)
E4            0     RR   5302-36-3/CN
                         ((S)-isomer)
E5            0     RR   5704-60-9/CN
                         (mono-HCl(+-)-isomer)
E6            0     RR   7349-37-3/CN
                         (mono-HCl(S)-isomer)
E7            0     RR   7388-03-6/CN
                         (mono-HCl(R)-isomer)
E8            0     RR   7413-36-7/CN
                         ((+-)-isomer)
E9            0     UF   1-(4-nitrophenyl)-2-isopropylaminoethanol/CN
E10           0     UF   inpea/CN
E11           0     UF   nifenalol monohydrochloride, (+-)-isomer/CN
E12           0     UF   nifenalol monohydrochloride, (R)-isomer/CN
E13           0     UF   nifenalol monohydrochloride, (S)-isomer/CN
E14           0     UF   nifenalol, (+-)-isomer/CN
E15           0     UF   nifenalol, (R)-isomer/CN
E16           0     UF   nifenalol, (S)-isomer/CN
                    HM   *Ethanolamines
                    NOTE adrenergic beta-blocker with good antiarrhythmic
                         properties; also tends to lower blood pressure &
                         provide protection against angina; minor
                         descriptor(75-86); on-line & INDEX MEDICUS search
                         ETHANOLAMINES (75-86);  RN given refers to parent cpd
                         without isomeric designation
                    PNTE minor descriptor (75-86); file maintained to
                         ETHANOLAMINES
********** END **********
```

EXPAND in /CT Thesaurus

```
=> E PLATELET AGGREGATION INHIBITORS+ALL/CT
E1            0   BT5   D Chemicals and Drugs/CT
E2            0    BT4   Chemical Actions and Uses/CT
E3            0     BT3   Pharmacologic Actions/CT
E4            0      BT2   Therapeutic Uses/CT
E5            0       BT1   Hematologic Agents/CT
E6           31        -->   Platelet Aggregation Inhibitors/CT
E7           31        MN    D27.505.954.502.780./CT
                        DC    an INDEX MEDICUS major descriptor
                        NOTE  Drugs or agents which antagonize or impair any
                              mechanism leading to blood platelet aggregation,
                              whether during the phases of activation and shape
                              change or following the dense-granule release
                              reaction and stimulation of the
                              prostaglandin-thromboxane system.
                        INDX  DF: PLATELET INHIB
                        AQ    AD AE AG AN BL CF CH CL CS CT DU EC HI IM IP ME
                              PD PK PO RE SD ST TO TU UR
                        PNTE  Blood Platelets (1966-1987)
                        PNTE  Platelet Adhesiveness (1972-1987)
                        PNTE  Platelet Aggregation (1976-1987)
                        HNTE  88
                        MHTH  NLM (1988)
E8            0         UF    Agents, Antiplatelet/CT
E9            0         UF    Aggregation Inhibitors, Platelet/CT
E10           0         UF    Antagonists, Blood Platelet/CT
E11           0         UF    Antagonists, Platelet/CT
E12           0         UF    Antiaggregants, Blood Platelet/CT
E13           0         UF    Antiaggregants, Platelet/CT
```

```
E14          0         UF    Antiplatelet Agents/CT
E15          0         UF    Antiplatelet Drugs/CT
E16          0         UF    Blood Platelet Aggregation Inhibitors/CT
E17          0         UF    Blood Platelet Antagonists/CT
E18          0         UF    Blood Platelet Antiaggregants/CT
E19          0         UF    Drugs, Antiplatelet/CT
E20          0         UF    Inhibitors, Platelet/CT
E21          0         UF    Inhibitors, Platelet Aggregation/CT
E22          0         UF    PLATELET AGGREGATION INHIB/CT
E23          0         UF    Platelet Antagonists/CT
E24          0         UF    Platelet Antiaggregants/CT
E25          0         UF    Platelet Inhibitors/CT
E26          4         NT1   Alprostadil/CT
E27         26         NT1   Aspirin/CT
E28         11         NT1   Dipyridamole/CT
E29          0         NT1   Disintegrins/CT
E30          7         NT1   Epoprostenol/CT
E31          0         NT1   Iloprost/CT
E32          3         NT1   Ketanserin/CT
E33          2         NT1   Milrinone/CT
E34          4         NT1   Pentoxifylline/CT
E35          2         NT1   S-Nitrosoglutathione/CT
E36          0         NT1   S-Nitrosothiols/CT
E37          0          NT2   S-Nitroso-N-Acetylpenicillamine/CT
E38          2          NT2   S-Nitrosoglutathione/CT
E39          4         NT1   Ticlopidine/CT
E40          1         NT1   Trapidil/CT
********** END **********
```

EXPAND in /MN Thesaurus

```
=> E D13.695.900.380.+ALL/MN
E1               BT7   D Chemicals and Drugs/MN
E2                BT6   Carbohydrates/MN
E3                 BT5   Glycosides/MN
E4                BT6   D Chemicals and Drugs/MN
E5                 BT5   Nucleic Acids, Nucleotides, and Nucleosides/MN
E6                  BT4   Nucleotides/MN
E7               BT7   D Chemicals and Drugs/MN
E8                BT6   Heterocyclic Compounds/MN
E9                 BT5   Heterocyclic Compounds, 2-Ring/MN
E10                 BT4   Purines/MN
E11                  BT3   Purine Nucleotides/MN
E12              BT7   D Chemicals and Drugs/MN
E13               BT6   Carbohydrates/MN
E14                BT5   Glycosides/MN
E15               BT6   D Chemicals and Drugs/MN
E16                BT5   Nucleic Acids, Nucleotides, and Nucleosides/MN
E17                 BT4   Nucleotides/MN
E18                  BT3   Ribonucleotides/MN
E19                   BT2   Guanine Nucleotides/MN
E20                    BT1   Guanosine Triphosphate/MN
E21                BT5   D Chemicals and Drugs/MN
E22                 BT4   Carbohydrates/MN
E23                  BT3   Glycosides/MN
E24                 BT4   D Chemicals and Drugs/MN
E25                  BT3   Nucleic Acids, Nucleotides, and Nucleosides/MN
E26                   BT2   Nucleotides/MN
E27                 BT4   D Chemicals and Drugs/MN
E28                  BT3   Inorganic Chemicals/MN
E29                 BT4   D Chemicals and Drugs/MN
E30                  BT3   Organic Chemicals/MN
E31                   BT2   Sulfur Compounds/MN
E32                    BT1   Thionucleotides/MN
E33                     -->   D13.695.900.380./MN
E34                     MH    Guanosine 5'-O-(3-Thiotriphosphate)/MN
```

```
                        RN    37589-80-3
                        DC    an INDEX MEDICUS major descriptor
                        NOTE  Guanosine 5'-(trihydrogen diphosphate),
                              monoanhydride with phosphorothioicacid. A
                              stable GTP analog which enjoys a variety of
                              physiological actions such as stimulation of
                              guanine nucleotide-binding proteins,
                              phosphoinositide hydrolysis, cyclic AMP
                              accumulation, and activation of specific
                              proto-oncogenes.
                        INDX  /biosyn /physiol permitted
                        AQ    AA AD AE AG AI AN BI BL CF CH CL CS CT DF DU EC
                              GE HI IM IP ME PD PH PK PORE SD SE ST TO TU UR
                        PNTE  Guanosine Triphosphate (1972-1990)
                        PNTE  Thionucleotides (1977-1990)
                        HNTE  91
                        MHTH  NLM (1991)
E35                     UF    GTP gamma S/MN
E36                     UF    GTPgammaS/MN
E37                     UF    GUANOSINE 5 O 3 THIOTRIPHOSPHATE/MN
E38                     UF    Guanosine 5'-(3-O-Thio)Triphosphate/MN
E39                     UF    Guanosine 5'-(gamma-S)Triphosphate/MN
E40                     UF    Guanosine 5'-(trihydrogen diphosphate),
                              P'-anhydride with phosphorothioic acid/MN
E41                     UF    gamma S, GTP/MN
E42                     UF    gamma Thio GTP/MN
E43                     UF    gamma-Thio-GTP/MN
********** END **********
```

DISPLAY BIB FOR EPUB AHEAD OF PRINT (NOTE: To manage the content of EPUB AHEAD OF PRINT records in your answer set use EPUB AHEAD OF PRINT/FS)

```
AN   2021000101     LMEDLINE (EPUB AHEAD OF PRINT)
DN   PubMed ID: 22033324
TI   Online information as a decision making aid for cancer patients:
     Recommendations from the Eurocancercoms project.
AU   Maddock Carol; Camporesi Silvia; Lewis Ian; Ahmad Kafait; Sullivan Richard
CS   Tenovus Cancer Charity, Gleider House, Ty Glas Road, Cardiff CF14 5BD,
     United Kingdom.
SO   European journal of cancer (Oxford, England : 1990), (2011 Oct 25) .
     Electronic Publication: 2011-10-25.
     Journal code: 9005373. E-ISSN: 1879-0852. L-ISSN: 0959-8049.
DT   Journal; Article; (JOURNAL ARTICLE)
LA   English
FS   EPUB AHEAD OF PRINT; NONMEDLINE; NONINDEXED
ED   Entered STN: 19 Mar 2012
     Last Updated on STN: 19 Mar 2012
```